PNU anthracycline substance-derived linker-load, pharmaceutical composition and application of PNU anthracycline substance-derived linker-load
By developing PNU anthracycline-derived linker-load compounds, the problems of toxicity limitations and pharmacokinetic control of anthracyclines in cancer chemotherapy were solved, achieving more efficient cancer cell delivery and release, and enhancing the anti-cancer effect.
CN120615015APending Publication Date: 2025-09-09默沙东有限责任公司
41 Cites 0 Cited by
Patent Information
- Application Number
- CN202380093031.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-04-19
- Filing Date
- 2023-12-18
- Publication Date
- 2025-09-09
AI Technical Summary
Technical Problem
The effectiveness of existing anthracyclines in cancer chemotherapy is limited by their toxicity, and there is room for improvement in the pharmacokinetic control and cancer cell delivery and release of antibody-drug conjugates.
Method used
A class of PNU anthracycline-derived linker-payload compounds was developed, which were combined with PEG units through maleimide- or sulfone-substituted pyridyl peptide linkers for the preparation of antibody-drug conjugates to improve drug delivery and release in cancer cells.
Benefits of technology
The delivery efficiency and release control of anthracyclines in cancer cells are improved, thereby enhancing the anti-cancer effect while reducing toxicity.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to linker-loadings, and pharmaceutically acceptable salts, solvates or stereoisomers thereof, comprising the structure of Formula I: # imgabs0. The disclosure also relates to pharmaceutical compositions comprising these compounds and the use of these compounds, intermediates and compositions thereof in the prevention or treatment of cancer and / or tumors.
Need to check novelty before this filing date? Find Prior Art